Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 14 February 2014 | By Alexander Gaffney, RAC,
In a major shift, the US Food and Drug Administration (FDA) today announced that it is looking to study the potential impacts of an alternate format for direct-to-consumer (DTC) television advertising, one in which companies would only be required to list the major-not all-risks associated with the use of a drug.
At present, companies are required to present the benefits and risks of a drug using a "fair balance" approach that gives equal weight to both the benefits of taking the drugs and the risks to the consumer who takes the drug. In addition to the "major statement" of risks-those risks most commonly associated with the drug-companies are also required to present other major risks that may occur considerably less frequently but to potentially devastating effect, up to and including death.
But while all that information may be required, regulators now seem increasingly concerned that its inclusion may be doing more harm than good. Could the advertisements, which sometimes span several minutes, be portraying an otherwise helpful and generally safe drug as overly dangerous?
And might consumers be subject to such a cavalcade of risks that they are no longer able to determine which are worth listening to? Might others stop taking a drug or avoid seeking a physician's care for unwarranted fear of a drug's side effects?
For now, it's hard to say without data.
But these critiques have long been raised by pharmaceutical marketers, and now in at least one medium, FDA says it's prepared to listen.
In a Federal Register announcement on 14 February 2014, FDA said it is considering the possibility that it should "limit the risks in the major statement to those that are serious and actionable, and include a disclosure to alert consumers that there are other product risks not included in the ad."
FDA floated one possible default disclosure:
"This is not a full list of risks and side effects. Talk to your doctor and read the patient labeling for [drug name] before starting it."
The agency says it plans to investigate the effectiveness of those disclosures, which it is calling a "limited risks plus disclosure" strategy, in upcoming studies it will conduct.
"Our hypothesis is that, relative to inclusion of the full major statement, providing limited risk information along with the disclosure about additional risks will promote improved consumer perception and understanding of serious and actionable drug risks." FDA wrote. "We will also investigate other questions such as whether overall drug risk and benefit perceptions are affected by these changes."
The agency's planned study will involve participants over the age of 18 assigned to one of four groups:
FDA anticipates a total of 500 participants taking part in an initial pilot study, with an additional 1,500 participants taking place in the main study.
Comments on the proposed study are due in 60 days.
News of the study also comes just two months after Focus postulated that FDA was preparing a "broad shift in the way it regulates DTC drug advertising." It would seem we were correct.
Federal Register Notice
Regulatory Focus newsletters
All the biggest regulatory news and happenings.